Your session is about to expire
← Back to Search
Ibrutinib + Pembrolizumab for Leukemia and Lymphoma
Study Summary
This trial will help determine the best dose of ibrutinib in combination with pembrolizumab for patients with CLL or MCL that has relapsed or progressed after prior therapy. The safety of this combination will also be studied.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am a man who can father a child and will use birth control during and for 4 months after the study.I haven't had cancer treatment with antibodies in the last 4 weeks or still have side effects.I have not received a live vaccine in the last 30 days.I am 18 years old or older.I agree to provide a recent biopsy sample of my tumor.I have taken a pregnancy test within the last 3 days and it was negative.I will use birth control during and for 4 months after the study.I have an immune system disorder or have been on steroids or immune-suppressing drugs recently.I have an active TB infection.I am not allergic to ibrutinib, pembrolizumab, or their ingredients.I have a history of HIV or active Hepatitis B or C.I have a history of or currently have non-infectious lung inflammation.I haven't had chemotherapy, targeted therapy, or radiation in the last 2 weeks.I have another cancer besides skin cancer that is getting worse or needs treatment.I have active brain metastases or cancer in the lining of my brain.I am currently being treated for an infection.I have been treated with drugs targeting PD-1, PD-L1, or PD-L2.My condition worsened despite being on a BTK inhibitor treatment.I am fully active or restricted in physically strenuous activity but can do light work.My recent tests show my organs are functioning well.I have been treated for an autoimmune disease in the last year.
- Group 1: Participants with MCL
- Group 2: Participants with CLL
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are you looking for more test subjects at the moment?
"Yes, this study is still open to new participants according to the clinicaltrials.gov listing. This trial was originally posted on July 14th, 2017 and updated last on August 22nd, 2022."
Does this research pertain to middle-aged adults?
"According to the eligibility criteria for this trial, the minimum age for enrollment is 18 and the maximum age is 99."
Who can sign up for this experiment?
"This trial is looking for 40 individuals who have leukemia or lymphoid and meet the following requirements: be willing to provide a tissue sample from a recent biopsy, be of age 18 or older, have a performance status of 0 or 1 on the ECOG Performance Scale, demonstrate adequate organ function, use contraception if of childbearing potential, and abstain from sexual activity if this is their usual lifestyle."
What therapeutic benefits has Pembrolizumab been shown to provide?
"Pembrolizumab can be used as part of a treatment plan for patients with malignant neoplasms, unresectable melanoma, and microsatellite instability high."
What other research has been conducted with Pembrolizumab?
"There are a total of 1153 clinical trials currently underway that involve Pembrolizumab. Of these, 145 have reached Phase 3. The majority of research is based in Houston, Texas; however, there are 43,225 locations running Pembrolizumab trials globally."
How many test subjects are part of this experiment?
"That is correct. The website clinicaltrials.gov has the most recent information on this study, which was updated on 8/22/2022. This trial posted on 7/14/2017 and is looking for 40 patients that meet the qualifications from 1 location."
Share this study with friends
Copy Link
Messenger